Title
Deep Brain Stimulation for Pediatric Dystonia: A Review of the Literature and Suggested Programming Algorithm
Date Issued
01 January 2022
Access level
open access
Resource Type
journal article
Author(s)
Gelineau-Morel R.
Kruer M.C.
Garris J.F.
Abu Libdeh A.
Barbosa D.A.N.
Coffman K.A.
Moon D.
Barton C.
Bruce A.B.
Larsh T.
Wu S.W.
Gilbert D.L.
O’Malley J.A.
Children’s National Hospital
Publisher(s)
SAGE Publications Inc.
Abstract
Deep brain stimulation (DBS) is an established intervention for use in pediatric movement disorders, especially dystonia. Although multiple publications have provided guidelines for deep brain stimulation patient selection and programming in adults, there are no evidence-based or consensus statements published for pediatrics. The result is lack of standardized care and underutilization of this effective treatment. To this end, we assembled a focus group of 13 pediatric movement disorder specialists and 1 neurosurgeon experienced in pediatric deep brain stimulation to review recent literature and current practices and propose a standardized approach to candidate selection, implantation target site selection, and programming algorithms. For pediatric dystonia, we provide algorithms for (1) programming for initial session and follow-up sessions, and (2) troubleshooting side effects encountered during programming. We discuss common side effects, how they present, and recommendations for management. This topical review serves as a resource for movement disorders specialists interested in using deep brain stimulation for pediatric dystonia.
Language
English
OCDE Knowledge area
NeurologÃa clÃnica
PediatrÃa
Subjects
Scopus EID
2-s2.0-85138292728
PubMed ID
Source
Journal of Child Neurology
ISSN of the container
08830738
Sponsor(s)
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (grant number T32HD069038).
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Gelineau-Morel receives support from the National Institutes of Health (NIH; NICHD) through a T32 Pediatric Clinical and Developmental Pharmacology Training Program (2T32HD069038-11). Michael C. Kruer receives grant support from the NIH, Medtronic, the Cerebral Palsy Alliance Research Foundation, Doris Duke Charitable Foundation, PTC Therapeutics, and BridgeBio, all outside of the submitted work. Keith A. Coffman has received honoraria and/or travel support from the Tourette Association of America/Centers for Disease Control and Prevention, the American Board of Psychiatry and Neurology, and the FamilieSCN2A foundation outside of the submitted work. He has served as a consultant for Lundbeck Pharmaceuticals, TEVA Pharmaceuticals, PTC Therapeutics, and EuMentis Therapeutics. He has received research support from the NIH (NICHD) outside the submitted work. Alonso Zea Vera has received travel support from the Child Neurology Society and has received research support from the Tourette Association of America, American Brain Foundation, and American Academy of Neurology, all outside the submitted work. Steve W. Wu receives support from NIH, outside the submitted work; he also consulted for Medtronic from 2018 to 2020. Donald L. Gilbert has received payment for medical expert opinions through Advanced Medical/Teladoc. He has served as a consultant for Applied Therapeutics and Eumentics Therapeutics. He has received research support from the NIH (NIMH) and the Department of Defense outside the submitted work. He has received book/publication royalties from Elsevier, Wolters Kluwer, and the Massachusetts Medical Society. Jennifer A. O’Malley has attended educational dinners hosted by Boston Scientific and Medtronic. All other authors have no conflicts of interest to disclose.
Sources of information:
Directorio de Producción CientÃfica
Scopus